[go: up one dir, main page]

SMT202000171T1 - Uso terapeutico di proteine morfogenetiche ossee - Google Patents

Uso terapeutico di proteine morfogenetiche ossee

Info

Publication number
SMT202000171T1
SMT202000171T1 SM20200171T SMT202000171T SMT202000171T1 SM T202000171 T1 SMT202000171 T1 SM T202000171T1 SM 20200171 T SM20200171 T SM 20200171T SM T202000171 T SMT202000171 T SM T202000171T SM T202000171 T1 SMT202000171 T1 SM T202000171T1
Authority
SM
San Marino
Prior art keywords
therapeutic use
bone morphogenetic
morphogenetic proteins
proteins
bone
Prior art date
Application number
SM20200171T
Other languages
English (en)
Inventor
Nicholas W Morrell
Wei Li
Paul D Upton
Original Assignee
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51453948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202000171(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cambridge Entpr Ltd filed Critical Cambridge Entpr Ltd
Publication of SMT202000171T1 publication Critical patent/SMT202000171T1/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/51Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1875Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10041Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/10041Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM20200171T 2014-07-10 2015-07-09 Uso terapeutico di proteine morfogenetiche ossee SMT202000171T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1412290.7A GB201412290D0 (en) 2014-07-10 2014-07-10 Novel use
PCT/GB2015/051989 WO2016005756A1 (en) 2014-07-10 2015-07-09 Therapeutic use of bone morphogenetic proteins
EP15739658.1A EP3166628B2 (en) 2014-07-10 2015-07-09 Therapeutic use of bone morphogenetic proteins

Publications (1)

Publication Number Publication Date
SMT202000171T1 true SMT202000171T1 (it) 2020-05-08

Family

ID=51453948

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20210323T SMT202100323T1 (it) 2014-07-10 2015-07-09 Proteine morfogenetiche ossee
SM20200171T SMT202000171T1 (it) 2014-07-10 2015-07-09 Uso terapeutico di proteine morfogenetiche ossee

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM20210323T SMT202100323T1 (it) 2014-07-10 2015-07-09 Proteine morfogenetiche ossee

Country Status (22)

Country Link
US (4) US10336800B2 (it)
EP (3) EP3669886B1 (it)
JP (1) JP6737770B2 (it)
KR (2) KR20230049757A (it)
CN (1) CN106661094B (it)
AU (1) AU2015287397B2 (it)
CA (1) CA2954221C (it)
CY (2) CY1123011T1 (it)
DK (2) DK3166628T3 (it)
ES (2) ES2876124T3 (it)
GB (1) GB201412290D0 (it)
HR (2) HRP20200418T1 (it)
HU (2) HUE048924T2 (it)
LT (2) LT3166628T (it)
MX (2) MX378431B (it)
PL (2) PL3166628T5 (it)
PT (2) PT3669886T (it)
RS (2) RS61961B1 (it)
RU (1) RU2733318C2 (it)
SI (2) SI3669886T1 (it)
SM (2) SMT202100323T1 (it)
WO (1) WO2016005756A1 (it)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
GB201603653D0 (en) * 2016-03-02 2016-04-13 Cambridge Entpr Ltd Combination Therapy
WO2018144968A1 (en) * 2017-02-06 2018-08-09 Acceleron Pharma Inc. Compositions and methods for treating heart failure
SG11202002590VA (en) 2017-11-02 2020-04-29 Bayer Ag Bispecific antibodies binding alk-1 and bmpr-2
CN107760779B (zh) * 2017-11-03 2020-10-16 中国医学科学院阜外医院 肺动脉高压相关的突变型bmp9基因及其应用
KR102790528B1 (ko) * 2017-12-12 2025-04-07 쿄와 기린 가부시키가이샤 항bmp10 항체 및 해당 항체를 유효 성분으로 하는, 고혈압 및 고혈압성 질환에 대한 치료제
CN111939245B (zh) * 2019-05-16 2024-03-01 龚笑海 一种心脏治疗和保护的药物组合物
EP4081240A4 (en) * 2019-12-03 2023-12-06 Acceleron Pharma Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF PULMONARY HYPERTENSION
KR20220021207A (ko) * 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물
WO2023012318A1 (en) * 2021-08-05 2023-02-09 Actelion Pharmaceuticals Ltd Bmp9 variant polypeptides and uses thereof
CN114317604B (zh) * 2022-03-04 2022-06-17 中国医学科学院阜外医院 一种自发性肺动脉高压模型及构建方法
CN120586063A (zh) * 2025-06-18 2025-09-05 中国人民解放军总医院第六医学中心 Bmp9抑制剂在制备用于治疗高血压的药物中的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US171355A (en) * 1875-12-21 Improvement in driers
WO1993000432A1 (en) 1991-06-25 1993-01-07 Genetics Institute, Inc. Bmp-9 compositions
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
ATE265529T1 (de) 1993-05-12 2004-05-15 Inst Genetics Llc Bmp-10 zusammensetzungen
AU6787594A (en) 1994-03-10 1995-09-25 Human Genome Sciences, Inc. Bone morphogenic protein-10
WO1996039431A1 (en) 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Bone morphogenic protein-10
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP1571159A1 (en) 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
WO2006130022A1 (en) 2005-05-30 2006-12-07 Agresearch Limited Modulation of ovulation by agonists and antagonists of bmprii
EP2056852A4 (en) 2006-07-27 2010-01-13 Centocor Ortho Biotech Inc BMP-7 VARIANTS COMPOSITIONS, METHODS AND USES
DK2087001T3 (en) * 2006-11-02 2017-02-06 Acceleron Pharma Inc ALK1 RECEPTOR AND LIGAND ANTAGONISTS AND APPLICATIONS THEREOF
CA2685306A1 (en) 2007-06-01 2008-12-11 Wyeth Methods and compositions for modulating bmp-10 activity
US8507501B2 (en) 2008-03-13 2013-08-13 The Brigham And Women's Hospital, Inc. Inhibitors of the BMP signaling pathway
WO2010114833A1 (en) 2009-04-01 2010-10-07 Indiana University Research And Technology Corporation Methods for treating diseases using a bone morphogenetic protein
WO2010115874A1 (en) 2009-04-07 2010-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
CN103492562B (zh) * 2011-02-03 2017-04-05 佐马技术有限公司 用于增强细菌中功能蛋白表达的方法和材料
CN108341863A (zh) 2011-04-20 2018-07-31 阿塞勒隆制药公司 内皮糖蛋白多肽及其用途
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
EP2970311A4 (en) 2013-03-14 2016-11-23 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
RS62011B1 (sr) * 2016-07-15 2021-07-30 Acceleron Pharma Inc Kompozicije koje sadrže polipeptide actriia za upotrebu u lečenju plućne hipertenzije
CN107760779B (zh) 2017-11-03 2020-10-16 中国医学科学院阜外医院 肺动脉高压相关的突变型bmp9基因及其应用
KR20220021207A (ko) 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물

Also Published As

Publication number Publication date
DK3669886T3 (da) 2021-05-25
RS60181B1 (sr) 2020-06-30
HUE048924T2 (hu) 2020-09-28
MX378431B (es) 2025-03-10
EP3906936A1 (en) 2021-11-10
RU2017102381A (ru) 2018-08-10
CY1123011T1 (el) 2021-10-29
BR112017000113A2 (pt) 2018-01-02
CA2954221A1 (en) 2016-01-14
PL3669886T3 (pl) 2021-09-13
LT3669886T (lt) 2021-06-10
HRP20200418T1 (hr) 2020-06-26
HUE054512T2 (hu) 2021-09-28
PT3166628T (pt) 2020-04-06
AU2015287397A1 (en) 2017-02-16
EP3166628A1 (en) 2017-05-17
LT3166628T (lt) 2020-04-10
US10336800B2 (en) 2019-07-02
GB201412290D0 (en) 2014-08-27
JP2017521074A (ja) 2017-08-03
US20170121383A1 (en) 2017-05-04
US20190359668A1 (en) 2019-11-28
CA2954221C (en) 2023-02-14
AU2015287397B2 (en) 2020-08-20
ES2876124T3 (es) 2021-11-11
WO2016005756A1 (en) 2016-01-14
PL3166628T3 (pl) 2020-06-15
RU2733318C2 (ru) 2020-10-01
JP6737770B2 (ja) 2020-08-12
SI3166628T1 (sl) 2020-07-31
EP3166628B2 (en) 2023-07-26
PL3166628T5 (pl) 2023-11-27
ES2770073T3 (es) 2020-06-30
RU2017102381A3 (it) 2019-02-28
SI3669886T1 (sl) 2021-08-31
CN106661094A (zh) 2017-05-10
EP3669886A1 (en) 2020-06-24
US20170209540A1 (en) 2017-07-27
KR20230049757A (ko) 2023-04-13
HRP20210734T1 (hr) 2021-06-11
ES2770073T5 (es) 2024-03-04
CY1124143T1 (el) 2022-05-27
EP3166628B1 (en) 2020-01-01
CN106661094B (zh) 2020-09-08
EP3669886B1 (en) 2021-02-24
MX2020011333A (es) 2020-11-24
PT3669886T (pt) 2021-05-25
US20240043485A1 (en) 2024-02-08
SMT202100323T1 (it) 2021-07-12
DK3166628T3 (da) 2020-03-09
KR20170029576A (ko) 2017-03-15
KR102519869B1 (ko) 2023-04-07
MX2017000448A (es) 2017-08-16
RS61961B1 (sr) 2021-07-30
US11572396B2 (en) 2023-02-07

Similar Documents

Publication Publication Date Title
PT3166628T (pt) Utilização terapêutica de proteínas morfogenéticas ósseas
SG11201700935VA (en) Medical/surgical implant
IL259281B (en) History of bipyrazolyl used in the treatment of autoimmune diseases
IL256985A (en) Compounds for inducing tissue formation and their uses
IL256980A (en) Compounds for inducing tissue formation and their uses
ZA201705847B (en) Treatment of pain
IL277377B (en) Prohemostatic proteins for the treatment of bleeding
IL286670B (en) Compounds for inducing tissue formation and their uses
IL256968A (en) Compounds for inducing tissue formation and uses thereof
GB201504413D0 (en) Treatment of disease
TWM489058U (en) Structure of medical tweezers
GB201414023D0 (en) Treatment of autoimmune diseases